An interventional study of TruGamma System and Optimal medical therapy (OMT) in Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency and Tricuspid Valve Disease, sponsored by Jiangsu Trulive Medical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Jiangsu Trulive Medical Co., Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Tricuspid Valve Insufficiency with a site in China — 19 open to participants now, 21 under way, none of them phase 3. Tricuspid Valve Insufficiency · China.
Among the 28 studies in Tricuspid Valve Insufficiency with a site in China, this one is the 5th largest by planned enrollment of the 16 interventional ones that give a count, is one of 5 that started in 2026, is one of 15 with no phase, reaches primary completion later than 15 of the 20 other live ones, and was the 25th registered.
229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.
Browse Tricuspid Valve Insufficiency studies →19 of the 28 studies in Tricuspid Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:
Shanghai Huihe Medical Technology Co., Ltd · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Haiyan Wang · Sites in China
Ages 18+
First Hospital of China Medical University · Sites in China
Ages 18+
Hangzhou Valgen Medtech Co., Ltd · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 60 across 129 interventional studies indexed under Tricuspid Valve Insufficiency.
Median enrollment 129 across the 16 interventional studies, 2,320 across the 12 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 28 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jiangsu Trulive Medical Co., Ltd as lead sponsor.
Jiangsu Trulive Medical Co., Ltd has 1 study filed under Tricuspid Valve Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Tricuspid Valve Insufficiency with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07292896First Hospital of China Medical UniversityA Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography | 2026-12 |
| NCT05595187Nanjing Medical UniversityConcomitant Tricuspid Repair in Patients With Left Heart Surgery | 2026-12-31 |
| NCT05194423Changhai HospitalTHE TRAVEL II TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve Via Jugular Vein | 2027-03 |
| NCT06663566Beijing Anzhen HospitalApplication of FAPI Visualization in the Assessment of Right Ventricular Dysfunction Due to Volume Overload | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 28 studies in Tricuspid Valve Insufficiency with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pivotal trial to evaluate the safety and effectiveness of the TruGamma tricuspid valve replacement system
The study is a prospective, multi-center, randomized controlled pivotal clinical trial to evaluate the safety and effectiveness of the TruGamma System with optimal medical therapy (OMT) compared to OMT alone in the treatment of patients with at least severe tricuspid regurgitation. Subjects will be followed at discharge, 30 days, 3 months, 6 months and annually through 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transcatheter tricuspid valve replacement with the TruGamma System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation.
Device: TruGamma System
Optimal medical therapy (OMT) alone in patients with tricuspid regurgitation
Drug: Optimal medical therapy (OMT)
Transcatheter tricuspid valve replacement with the TruGamma System in conjunction with OMT
Also known as: Transcatheter tricuspid valve replacement
Optimal Medical Therapy
Hierarchical composite endpoint including: Kansas City Cardiomyopathy Questionnaire (KCCQ) improvement, New York Heart Association (NYHA) functional class improvement, and 6-minute walk test distance improvement
Comparison of number of wins with composite endpoint event improvement between experimental and active comparator arm.KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better health status.NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).
Time frame: 12months
Tricuspid Regurgitation (TR) severity
Comparison of percentage of patients with tricuspid regurgitation of 2+ or less between experimental and active comparator arm.TR severity will be assessed using the 5-grade scale with the addition of "none/trace" to represent the lack of TR (scale: none/trace, mild, moderate, severe, massive, torrential). Lower grades of TR are better.
Time frame: 12months
Rate of Major Adverse Events (MAE)
Rate of Major Adverse Events (MAE) in experimental arm(TruGamma System in conjunction with OMT)
Time frame: 30 days
Procedural success rate
Procedural success rate in experimental arm.Criteria for procedural success (all of the following items shall be satisfied): No intraprocedural death or stroke;The device is successfully delivered via the jugular vein into the right atrium, across the tricuspid valve and into the right ventricle, followed by deployment of the prosthetic valve and removal of the delivery system;The implanted valve is positioned at an appropriate anatomical site;No moderate or greater transvalvular regurgitation, no moderate or greater paravalvular leakage, and no tricuspid stenosis of the implanted valve;No device-related forward flow obstruction or pulmonary embolism; No device- or access site-related complications requiring urgent reoperation or other reintervention within 24 hours after the procedure.
Time frame: Immediately after procedure
Clinical success rate
Clinical success rate in experimental arm.Criteria for clinical success (all of the following shall be met): No procedural death or stroke; The implanted valve is positioned at an appropriate anatomical site, with no moderate or greater transvalvular regurgitation, no moderate or greater paravalvular leakage and no tricuspid stenosis. There are no device- or access site-related complications requiring reoperation or other reintervention; No major adverse events (MAE) related to the device or procedure.
Time frame: 30 days
System performance evaluation
Intraoperative performance evaluation of the transcatheter tricuspid valve system, including overall device performance, ease of use of the delivery system, compatibility of the delivery system with the loaded prosthetic valve, priming performance, visualization, pushability and trackability of the delivery system, compatibility among all components of the delivery system, hemostatic performance of the delivery system, positioning function for the prosthetic valve, leaflet capture and control function, interaction between the system and adjacent anatomical structures, stability and operability during valve deployment, and retraction performance. Thrombosis or embolism shall also be assessed.The evaluation is graded into four levels: Excellent, Good, Fair, Poor.
Time frame: Immediately after procedure
Tricuspid Regurgitation (TR) grade reduction
Comparison of number of participants with reduction in TR between between experimental and active comparator arm.TR severity will be assessed using the 5-grade scale with the addition of "none/trace" to represent the lack of TR (scale: none/trace, mild, moderate, severe, massive, torrential). Lower grades of TR are better.
Time frame: 30 days, 6 months, 12 months
Change in KCCQ from baseline
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline.KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better health status.
Time frame: 30 days, 6 months, 12 months
Reduction in New York Heart Association (NYHA) functional class
Total number of patients with NYHA functional class improvement of at least 1 class.NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).
Time frame: 30 days, 6 months, 12 months
Change in 6MWD from baseline
Change in 6MWD from baseline
Time frame: 30 days, 6 months, 12 months
Change in Quality of Life (QOL)
Comparison of percentage of patients with improvement in any one of the three indicators - KCCQ score, NYHA functional class, or 6-minute walk test distance between experimental and active comparator arm. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better health status.NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).
Time frame: 30 days, 6 months, 12 months
Heart failure hospitalizations
Total number of patients with at least one hospital admission due to heart failure
Time frame: 30 days, 6 months, 12 months
Edema grade
4-level assessment of edema severity
Time frame: 30 days, 6 months, 12 months
All-Cause Mortality
Total number of deaths from any cause
Time frame: 30 days, 6 months, 12 months
Tricuspid valve re-intervention (percutaneous or surgical)
Total number of patients with at least one non-elective tricuspid valve re-intervention
Time frame: 30 days, 6 months, 12 months
Rate of Major Adverse Events (MAE)
Rate of Major Adverse Events (MAE) in treatment arm(TruGamma System in conjunction with OMT)
Time frame: 6 months, 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Aug 2028, 29 months after the start.
Of 86 interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 29 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tricuspid Valve Insufficiency →